You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMoclobemide
Accession NumberDB01171  (APRD00603)
TypeSmall Molecule
GroupsApproved
Description

A reversible monoamine oxidase inhibitor (MAOI) selective for isoform A (RIMA) used to treat major depressive disorder.

Structure
Thumb
Synonyms
4-Chlor-N-(2-morpholinoethyl)benzamid
4-Chloro-N-(2-(4-morpholinyl)ethyl)benzamide
4-Chloro-N-(2-morpholin-4-yl-ethyl)-benzamide
Aurorix
Moclaime
Moclamide
Moclamine
Moclobemid
Moclobemida
Moclobemide
Moclobemidum
p-Chloro-N-(2-morpholinoethyl)benzamide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-moclobemide Tablets 150mgtablet150 mgoralDominion Pharmacal2001-02-15Not applicableCanada
Dom-moclobemide Tablets 300mgtablet300 mgoralDominion Pharmacal2001-02-15Not applicableCanada
Manerixtablet300 mgoralValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
Manerixtablet150 mgoralValeant Canada Lp Valeant Canada S.E.C.1992-12-31Not applicableCanada
Manerix Tab 100mgtablet100 mgoralHoffmann La Roche Limited1992-12-311997-12-04Canada
Moclobemide-100tablet100 mgoralPro Doc Limitee1998-06-022009-07-23Canada
Moclobemide-150tablet150 mgoralPro Doc Limitee1998-06-022009-07-23Canada
Nu-moclobemidetablet150 mgoralNu Pharm Inc1998-07-282012-09-04Canada
Nu-moclobemidetablet100 mgoralNu Pharm Inc1998-07-292012-09-04Canada
PMS-moclobemidetablet300 mgoralPharmascience Inc2001-01-08Not applicableCanada
PMS-moclobemidetablet150 mgoralPharmascience Inc2001-01-08Not applicableCanada
Ratio-moclobemide - Tab 150mgtablet150 mgoralRatiopharm Inc Division Of Teva Canada Limited1997-10-012006-08-04Canada
Ratio-moclobemide - Tab 300mgtablet300 mgoralRatiopharm Inc Division Of Teva Canada Limited1999-07-122006-08-04Canada
Riva-moclobemide 150mg Tabletstablet150 mgoralLaboratoire Riva Inc1999-08-302003-07-28Canada
Riva-moclobemide 300mg Tabletstablet300 mgoralLaboratoire Riva Inc1999-08-302003-07-28Canada
Teva-moclobemidetablet100 mgoralTeva Canada Limited1999-05-20Not applicableCanada
Teva-moclobemidetablet300 mgoralTeva Canada Limited1999-05-20Not applicableCanada
Teva-moclobemidetablet150 mgoralTeva Canada Limited1999-05-20Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-moclobemidetablet100 mgoralApotex Inc1997-09-18Not applicableCanada
Apo-moclobemidetablet300 mgoralApotex Inc1999-07-14Not applicableCanada
Apo-moclobemidetablet150 mgoralApotex Inc1997-09-18Not applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AurorixNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIPJ0Y7AZB63
CAS number71320-77-9
WeightAverage: 268.739
Monoisotopic: 268.097855505
Chemical FormulaC13H17ClN2O2
InChI KeyInChIKey=YHXISWVBGDMDLQ-UHFFFAOYSA-N
InChI
InChI=1S/C13H17ClN2O2/c14-12-3-1-11(2-4-12)13(17)15-5-6-16-7-9-18-10-8-16/h1-4H,5-10H2,(H,15,17)
IUPAC Name
4-chloro-N-[2-(morpholin-4-yl)ethyl]benzamide
SMILES
ClC1=CC=C(C=C1)C(=O)NCCN1CCOCC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 4-halobenzoic acids and derivatives. These are benzoic acids or derivatives carrying a halogen atom at the 4-position of the benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct Parent4-halobenzoic acids and derivatives
Alternative Parents
Substituents
  • 4-halobenzoic acid or derivatives
  • Benzamide
  • Benzoyl
  • Halobenzene
  • Chlorobenzene
  • Oxazinane
  • Morpholine
  • Aryl halide
  • Aryl chloride
  • Tertiary aliphatic amine
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of depression.
PharmacodynamicsMoclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility.
Mechanism of actionThe mechanism of action of moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms.
Related Articles
AbsorptionWell absorbed from the gastrointestinal tract (> 95%). The presence of food reduces the rate but not the extent of absorption. Hepatic first pass metabolism reduces bioavailability to 45-70% following administration of a single dose, but increases to 80% with multiple dosing as a result of saturation of the first pass effect. Peak plasma concentrations are reached within 1 - 2 hours following oral administration.
Volume of distributionNot Available
Protein bindingApproximately 50% (primarily to albumin)
Metabolism

Moclobemide is almost completely metabolized in the liver by Cytochrome P450 2C19 and 2D6.

Route of eliminationNot Available
Half life1-2 hours (4 hours in cirrhotic patients); metabolites are renally excreted
ClearanceNot Available
ToxicityLD50 (mouse) is 730mg/kg and LD50 (rat) is 1,300mg/kg. Signs of toxicity include hypertension, drowsiness, dizziness, confusion, tremors, headache, agitation, muscle rigidity and seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9838
Blood Brain Barrier+0.9691
Caco-2 permeable-0.5602
P-glycoprotein substrateSubstrate0.6652
P-glycoprotein inhibitor IInhibitor0.6892
P-glycoprotein inhibitor IINon-inhibitor0.8637
Renal organic cation transporterNon-inhibitor0.5691
CYP450 2C9 substrateNon-substrate0.8538
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.5723
CYP450 1A2 substrateNon-inhibitor0.9138
CYP450 2C9 inhibitorNon-inhibitor0.8989
CYP450 2D6 inhibitorNon-inhibitor0.8081
CYP450 2C19 inhibitorInhibitor0.8024
CYP450 3A4 inhibitorNon-inhibitor0.9384
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5956
Ames testNon AMES toxic0.6867
CarcinogenicityNon-carcinogens0.8727
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.6098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7135
hERG inhibition (predictor II)Inhibitor0.5646
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral150 mg
Tabletoral300 mg
Prices
Unit descriptionCostUnit
Manerix 300 mg Tablet1.34USD tablet
Apo-Moclobemide 300 mg Tablet0.75USD tablet
Novo-Moclobemide 300 mg Tablet0.75USD tablet
Pms-Moclobemide 300 mg Tablet0.75USD tablet
Manerix 150 mg Tablet0.68USD tablet
Apo-Moclobemide 150 mg Tablet0.38USD tablet
Novo-Moclobemide 150 mg Tablet0.38USD tablet
Pms-Moclobemide 150 mg Tablet0.38USD tablet
Apo-Moclobemide 100 mg Tablet0.26USD tablet
Novo-Moclobemide 100 mg Tablet0.26USD tablet
Nu-Moclobemide 100 mg Tablet0.26USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.12 mg/mLALOGPS
logP1.56ALOGPS
logP1.45ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)14.73ChemAxon
pKa (Strongest Basic)6.02ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.57 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity71.93 m3·mol-1ChemAxon
Polarizability28.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0udi-2900000000-c3230d46878446405991View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN06AG02
AHFS Codes
  • 28:16.04.12
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AcepromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acepromazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Acetophenazine.
AclidiniumAclidinium may increase the anticholinergic activities of Moclobemide.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Moclobemide.
AmisulprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Amisulpride.
AmitriptylineMoclobemide may increase the serotonergic activities of Amitriptyline.
AmphetamineMoclobemide may increase the hypertensive activities of Amphetamine.
ApraclonidineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Apraclonidine.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Moclobemide.
AtomoxetineMoclobemide may increase the central neurotoxic activities of Atomoxetine.
AtropineMoclobemide may increase the hypertensive activities of Atropine.
BenzquinamideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Benzquinamide.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Moclobemide.
BezafibrateThe risk or severity of adverse effects can be increased when Moclobemide is combined with Bezafibrate.
BortezomibThe metabolism of Moclobemide can be decreased when combined with Bortezomib.
Botulinum Toxin Type AMoclobemide may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BMoclobemide may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Brimonidine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide.
BupropionMoclobemide may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Moclobemide.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Moclobemide.
CarphenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Carphenazine.
CathinoneMoclobemide may increase the hypertensive activities of Cathinone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlormezanone.
ChlorpromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Chlorprothixene.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Moclobemide.
CimetidineThe metabolism of Moclobemide can be decreased when combined with Cimetidine.
CimetropiumMoclobemide may increase the anticholinergic activities of Cimetropium Bromide.
ClemastineMoclobemide may increase the anticholinergic activities of Clemastine.
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Moclobemide resulting in a loss in efficacy.
ClozapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Clozapine.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Moclobemide.
CyproheptadineMoclobemide may increase the anticholinergic activities of Cyproheptadine.
DabrafenibThe serum concentration of Moclobemide can be decreased when it is combined with Dabrafenib.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Moclobemide.
DexmethylphenidateMoclobemide may increase the hypertensive activities of Dexmethylphenidate.
DextromethorphanMoclobemide may increase the serotonergic activities of Dextromethorphan.
DiethylpropionMoclobemide may increase the hypertensive activities of Diethylpropion.
DomperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Domperidone.
DoxapramMoclobemide may increase the hypertensive activities of Doxapram.
DoxylamineMoclobemide may increase the anticholinergic activities of Doxylamine.
DronabinolMoclobemide may increase the tachycardic activities of Dronabinol.
DroperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Droperidol.
EluxadolineMoclobemide may increase the activities of Eluxadoline.
EpinephrineMoclobemide may increase the hypertensive activities of Epinephrine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Moclobemide.
FencamfamineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fencamfamine.
FlupentixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluphenazine.
FluspirileneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Fluspirilene.
FluvoxamineThe metabolism of Moclobemide can be decreased when combined with Fluvoxamine.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Moclobemide is combined with Glucagon recombinant.
GranisetronGranisetron may increase the serotonergic activities of Moclobemide.
HaloperidolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Haloperidol.
HydrocodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydrocodone.
HydromorphoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Hydromorphone.
Insulin HumanMoclobemide may increase the hypoglycemic activities of Insulin Regular.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Moclobemide.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Moclobemide.
IsomethepteneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Isometheptene.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Moclobemide.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Moclobemide.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Moclobemide.
LevonordefrinMoclobemide may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Moclobemide.
LoxapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Loxapine.
LuliconazoleThe serum concentration of Moclobemide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Moclobemide can be decreased when it is combined with Lumacaftor.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Moclobemide.
MequitazineMoclobemide may increase the anticholinergic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mesoridazine.
MethadoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methadone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methotrimeprazine.
MethyldopaThe risk or severity of adverse effects can be increased when Moclobemide is combined with Methyldopa.
Methylene blueMoclobemide may increase the serotonergic activities of Methylene blue.
MethylphenidateMoclobemide may increase the hypertensive activities of Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Metoclopramide.
MianserinMoclobemide may increase the neurotoxic activities of Mianserin.
MidodrineMoclobemide may increase the hypertensive activities of Midodrine.
MirabegronThe risk or severity of adverse effects can be increased when Moclobemide is combined with Mirabegron.
MirtazapineMoclobemide may increase the central neurotoxic activities of Mirtazapine.
MolindoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Morphine.
MoxonidineMoclobemide may increase the hypotensive activities of Moxonidine.
NorepinephrineMoclobemide may increase the hypertensive activities of Norepinephrine.
OlanzapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Olanzapine.
OndansetronThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ondansetron.
OrciprenalineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Orciprenaline.
OxycodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Moclobemide.
PaliperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Paliperidone.
PantoprazoleThe metabolism of Pantoprazole can be decreased when combined with Moclobemide.
ParoxetineMoclobemide may increase the serotonergic activities of Paroxetine.
PerphenazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Perphenazine.
PethidineMoclobemide may increase the serotonergic activities of Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Moclobemide.
PhenytoinThe metabolism of Moclobemide can be increased when combined with Phenytoin.
PholcodinePholcodine may increase the serotonergic activities of Moclobemide.
PimozideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Pimozide.
PiperacetazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Piperacetazine.
PizotifenMoclobemide may increase the anticholinergic activities of Pizotifen.
Potassium ChlorideMoclobemide may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Moclobemide.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Moclobemide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Moclobemide.
PromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Promazine.
QuetiapineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Quetiapine.
RamosetronMoclobemide may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Moclobemide.
RemoxiprideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Remoxipride.
ReserpineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Reserpine.
RisperidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Risperidone.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Moclobemide.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Moclobemide.
SertindoleThe risk or severity of adverse effects can be increased when Moclobemide is combined with Sertindole.
SufentanilSufentanil may increase the serotonergic activities of Moclobemide.
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Moclobemide.
TacrineThe therapeutic efficacy of Moclobemide can be decreased when used in combination with Tacrine.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Moclobemide.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Moclobemide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Moclobemide.
TetryzolineMoclobemide may increase the hypertensive activities of Tetryzoline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Moclobemide.
ThiothixeneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.
TiotropiumMoclobemide may increase the anticholinergic activities of Tiotropium.
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Moclobemide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Moclobemide.
TopiramateThe risk or severity of adverse effects can be increased when Moclobemide is combined with Topiramate.
TramadolTramadol may increase the neuroexcitatory activities of Moclobemide.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Moclobemide.
TrazodoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trazodone.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Moclobemide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Moclobemide is combined with Triflupromazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Moclobemide.
VenlafaxineMoclobemide may increase the serotonergic activities of Venlafaxine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Moclobemide is combined with Ziprasidone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Moclobemide is combined with Zuclopenthixol.
Food Interactions
  • Food slows absorption a little. Avoid alcohol. Take after meals in order to minimize the risk of interaction with tyramine.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Berlin I, Zimmer R, Thiede HM, Payan C, Hergueta T, Robin L, Puech AJ: Comparison of the monoamine oxidase inhibiting properties of two reversible and selective monoamine oxidase-A inhibitors moclobemide and toloxatone, and assessment of their effect on psychometric performance in healthy subjects. Br J Clin Pharmacol. 1990 Dec;30(6):805-16. [PubMed:1705137 ]
  3. Fulton B, Benfield P: Moclobemide. An update of its pharmacological properties and therapeutic use. Drugs. 1996 Sep;52(3):450-74. [PubMed:8875133 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Fisar Z, Hroudova J, Raboch J: Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers. Neuro Endocrinol Lett. 2010;31(5):645-56. [PubMed:21200377 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23